168.94 USD
-0.76 (-0.45%)
168.55 USD
-0.39 (-0.23%)
Taking everything into account, JAZZ scores 4 out of 10 in our fundamental rating. JAZZ was compared to 191 industry peers in the Pharmaceuticals industry. While JAZZ is still in line with the averages on profitability rating, there are concerns on its financial health. JAZZ may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
In the past year JAZZ was profitable.
JAZZ had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
In the past 5 years JAZZ always reported a positive cash flow from operatings.
1.2 Ratios
JAZZ's Return On Assets of -3.24% is fine compared to the rest of the industry. JAZZ outperforms 73.82% of its industry peers.
The Return On Equity of JAZZ (-9.31%) is better than 74.87% of its industry peers.
With an excellent Return On Invested Capital value of 3.95%, JAZZ belongs to the best of the industry, outperforming 82.20% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 12.85%.
The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(3.95%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROIC | 3.95% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
In the last couple of years the Profit Margin of JAZZ has declined.
The Operating Margin of JAZZ (10.92%) is better than 83.25% of its industry peers.
JAZZ's Operating Margin has declined in the last couple of years.
The Gross Margin of JAZZ (88.49%) is better than 90.58% of its industry peers.
In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for JAZZ has been reduced compared to 1 year ago.
The number of shares outstanding for JAZZ has been increased compared to 5 years ago.
JAZZ has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.54, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of JAZZ (1.54) is comparable to the rest of the industry.
The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of JAZZ (4.33) is better than 83.25% of its industry peers.
JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.09, JAZZ is not doing good in the industry: 73.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.54 |
ROIC/WACC0.56
WACC7.08%
2.3 Liquidity
JAZZ has a Current Ratio of 1.65. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.65, JAZZ is doing worse than 66.49% of the companies in the same industry.
A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
JAZZ has a Quick ratio of 1.44. This is in the lower half of the industry: JAZZ underperforms 62.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for JAZZ have decreased strongly by -58.39% in the last year.
The Earnings Per Share has been growing slightly by 5.47% on average over the past years.
The Revenue has been growing slightly by 4.14% in the past year.
Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 13.48% on average per year.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
3.2 Future
Based on estimates for the next years, JAZZ will show a small growth in Earnings Per Share. The EPS will grow by 7.82% on average per year.
The Revenue is expected to grow by 7.13% on average over the next years.
EPS Next Y-61.13%
EPS Next 2Y4.45%
EPS Next 3Y6.19%
EPS Next 5Y7.82%
Revenue Next Year4.61%
Revenue Next 2Y5.72%
Revenue Next 3Y6.18%
Revenue Next 5Y7.13%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 20.70 indicates a rather expensive valuation of JAZZ.
JAZZ's Price/Earnings ratio is rather cheap when compared to the industry. JAZZ is cheaper than 80.10% of the companies in the same industry.
JAZZ is valuated rather cheaply when we compare the Price/Earnings ratio to 26.34, which is the current average of the S&P500 Index.
JAZZ is valuated cheaply with a Price/Forward Earnings ratio of 7.31.
Based on the Price/Forward Earnings ratio, JAZZ is valued cheaper than 91.62% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.56, JAZZ is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.7 | ||
| Fwd PE | 7.31 |
4.2 Price Multiples
84.82% of the companies in the same industry are more expensive than JAZZ, based on the Enterprise Value to EBITDA ratio.
92.67% of the companies in the same industry are more expensive than JAZZ, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.29 | ||
| EV/EBITDA | 11.29 |
4.3 Compensation for Growth
The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.79
EPS Next 2Y4.45%
EPS Next 3Y6.19%
5. Dividend
5.1 Amount
No dividends for JAZZ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
168.94
-0.76 (-0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners101.9%
Inst Owner Change-1.47%
Ins Owners2.48%
Ins Owner Change-0.72%
Market Cap10.27B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts84.17
Price Target212.17 (25.59%)
Short Float %8.22%
Short Ratio4.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)9.73%
PT rev (3m)11.4%
EPS NQ rev (1m)4.07%
EPS NQ rev (3m)11.63%
EPS NY rev (1m)53.27%
EPS NY rev (3m)53.97%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-0.84%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.7 | ||
| Fwd PE | 7.31 | ||
| P/S | 2.47 | ||
| P/FCF | 8.29 | ||
| P/OCF | 7.38 | ||
| P/B | 2.59 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.29 |
EPS(TTM)8.16
EY4.83%
EPS(NY)23.12
Fwd EY13.68%
FCF(TTM)20.39
FCFY12.07%
OCF(TTM)22.9
OCFY13.56%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)N/A
PEG (5Y)3.79
Graham Number109.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROCE | 5% | ||
| ROIC | 3.95% | ||
| ROICexc | 5.1% | ||
| ROICexgc | 55.75% | ||
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% | ||
| FCFM | 29.8% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.8 | ||
| Cap/Depr | 22.29% | ||
| Cap/Sales | 3.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 122.16% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.54 |
F-Score5
WACC7.08%
ROIC/WACC0.56
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-61.13%
EPS Next 2Y4.45%
EPS Next 3Y6.19%
EPS Next 5Y7.82%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.61%
Revenue Next 2Y5.72%
Revenue Next 3Y6.18%
Revenue Next 5Y7.13%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-59.78%
EBIT Next 3Y7.39%
EBIT Next 5Y9.15%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
What is the valuation status of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
How financially healthy is JAZZ PHARMACEUTICALS PLC?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
Can you provide the expected EPS growth for JAZZ stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -61.13% in the next year.